The latest new deal is a sign that made in China cancer drugs continue to generate interest from outside the country, due in part to increasing competition in the domestic immuno-oncology market.
US biotech firm Coherus BioSciences, Inc. has agreed to develop an immuno-oncology antibody from Shanghai Junshi Biosciences Co., Ltd
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?